Navigation Links
Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers
Date:2/22/2010

Biotech leaders enable Talaris’ capacity to deliver unprecedented, cross-functional expertise for all phases of drug development.

(PRWEB) February 22, 2010 -- In a move that forms one of biotech's most experienced strategic drug development groups, a team of veteran industry executives has joined Talaris Advisors, strengthening the company's capacity to provide expertise for all phases of drug development. Talaris works with biotech managers, companies and investors to optimize their use of capital and maximize exit outcomes for drug development programs.

Led by Mark J. Pykett, Chief Executive Officer, the Talaris management team has added the following industry veterans: Noel Cusack, PhD, Senior Vice President Nonclinical Development; Susan Flint, Senior Vice President Drug Development; Mark R. Hurtt, MD, Chief Medical Officer; Richard Thorn, PhD, Senior Vice President CMC; and James Weston, Senior Vice President Regulatory Affairs and Quality.

"Real strategic drug development expertise is determined by a team's insight and ability to accelerate milestones when taking a project through a wide range of regulatory scenarios and by creating a range of exit options based on the commercial and medical value of the assets. Our clients and investors are excited by Talaris’ expansion because it confirms our ability to provide this level of expertise and deftly address the complexities of drug development particularly in the current environment,” comments Mark J. Pykett, Talaris CEO. "Each new manager is a distinguished leader who has an average of 30 years of experience, in addition to having important networks and relationships to provide the best performance outcomes for drug compounds and investors."

By any measure, the drug development industry is challenged by the escalating cost and time it takes to develop drugs combined with increasingly complex and challenging regulatory, reimbursement and financing environments. Biotech leaders are working hard to find ways to improve both efficiency and effectiveness in drug development without losing key drivers for innovation. Biotech companies and investors engage Talaris to avoid the typical ramp-up, wind-down or carrying costs associated with drug development management while delivering integrated risk and cost optimized development programs.

The Talaris management team is composed of recognized leaders whose expertise spans the continuum of all key development disciplines: non-clinical, regulatory, medical, clinical operations, manufacturing and quality.

The industry veterans enhance Talaris’ capacity to manage projects strategically and successfully, having managed hundreds of development programs, clinical trials and regulatory submissions. In their careers with companies such as Pfizer, DuPont, Baxter and others, the team has taken over 30 products through to the market.

About Talaris Advisors
Talaris Advisors works with biotech managers, companies and investors to optimize the use of capital and exit outcomes for drug development programs. Veteran team members, averaging 30 years of drug development experience, design and implement strategies that improve success rates, build multiple exit options and maximize investment returns for therapeutic drug assets. We align the commercial and regulatory requirements of drug candidates in development programs to reduce risk and time factors in pre-IND to Phase II proof-of-concept development, improving their odds for regulatory and commercial success. For investors, our integrated portfolio approach diversifies intrinsic investment risks. Members of the Talaris team have successfully completed more than 125 clinical studies and advanced more than 30 drug products through to the market. The company is headquartered in Hopkinton, Massachusetts. Please visit Talaris at www.talarisadvisors.com.

###

Read the full story at http://www.prweb.com/releases/Talaris_Advisors/drug_development/prweb3626744.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members
2. FDA Advisors Declare FDA Science and Mission at Risk
3. Perceptive Informatics Appoints Medical Imaging Scientific Advisors
4. NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo
5. FDA Advisors Declare FDA Science and Mission at Risk
6. Brian Bastis Elected as National CPA Health Care Advisors Association Executive Committee President
7. Cosmetic Bootcamp Announces Record Attendance and Sponsorship and Names Members of Its Board of Advisors
8. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
9. As Consumers Feel Financial Burden of Increasing Health Care Costs, Health Plans Have Opportunity to Address Unmet Consumer Needs and Become Trusted Advisors
10. SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray
11. Emageon Selects Jefferies & Company and SunTrust Robinson Humphrey as Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers 
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: